ライフサイエンスコーパス: guanylate cyclase

1 s a vital ANF signal transducer motif of the guanylate cyclase.

2 ers include the mammalian NO sensor, soluble guanylate cyclase.

3 capability to the regulatory site in soluble guanylate cyclase.

4 at are not affected by inhibitors of soluble guanylate cyclase.

5 nists or inhibitors of nitric oxide (NO) and guanylate cyclase.

6 an higher apparent affinity with its target guanylate cyclase.

7 y interrupts signalling from nitric oxide to guanylate cyclase.

8 differentiated U937 cells that lack soluble guanylate cyclase.

9 ibitors of Gbetagamma, Akt, NOS, and soluble guanylate cyclase.

10 after blockade of NO synthase or of soluble guanylate cyclase.

11 g ischemia was associated with activation of guanylate cyclase.

12 a stimulatory effect of UVA light on soluble guanylate cyclase.

13 oxaline-1-one (ODQ), an inhibitor of soluble guanylate cyclase.

14 from targeting of the haem moiety of soluble guanylate cyclase.

15 st sensitive target of NO signaling, soluble guanylate cyclase.

16 ivate, and the subsequent generation cGMP by guanylate cyclase.

17 in sepsis and its relationship with soluble guanylate cyclase.

18 fine a new transduction paradigm of membrane guanylate cyclases.

19 f the subfamily of Ca(2+)-modulated membrane guanylate cyclases.

20 domains of classical nitric-oxide-regulated guanylate cyclases.

21 cyclic GMP-gated cation channels and distal guanylate cyclases.

22 protein-coupled receptor kinase 1 (GRK1) and guanylate cyclase 1 (GC1) has been suggested to play a r

23 was to examine the effects of the absence of guanylate cyclase 1 (GC1) on light-driven protein transl

24 ophy caused by loss-of-function mutations in guanylate cyclase 1 (GC1), a key member of the phototran

25 One gene, guanylate cyclase 1 alpha 3 (GUCY1A3), showed differenti

26 Concomitantly, guanylate cyclase 1, cone T alpha-subunit, cone phosphod

27 ignaling (Nitric Oxide Synthase 3 [NOS3] and Guanylate Cyclase 1, Soluble, Alpha 3 [GUCY1A3]) with a

28 in 2); glucokinase (hexokinase 4) regulator; guanylate cyclase 1, soluble, beta 3; MYST histone acety

29 s (GCAP1 and GCAP2) to their membrane target guanylate cyclase 1.

30 Retinal guanylate cyclases 1 and 2 (GC1 and GC2) are responsible

31 l delivery of AAV5 vectors containing murine guanylate cyclase-1 (GC1) cDNA driven by either photorec

32 function and survival are compromised in the guanylate cyclase-1 (GC1) knockout mouse.

33 Treatment with PKG inhibitor and deletion of guanylate cyclase-1 (GC1), the enzyme producing cGMP in

34 e elucidated this dependency by showing that guanylate cyclase-1 is a novel rhodopsin-binding protein

35 Indeed, we demonstrated that guanylate cyclase-1, producing the cGMP second messenger

36 ons in GUCY2D, the gene that encodes retinal guanylate cyclase-1.

37 peripherin, early growth response 1, soluble guanylate cyclase 1A3 and placental growth factor protei

38 ing identified a single-base substitution in guanylate cyclase 2D, membrane (retina-specific) gene (G

39 -deficient mice (moderate achromatopsia) and guanylate cyclase 2e-deficient mice (LCA with slower con

40 eotide-gated channel B subunit-deficient and guanylate cyclase 2e-deficient mice decreased about 40%

41 roach are the full-length mouse homologue of guanylate cyclase 2F (GUCY2F) and a carboxy-truncated sp

42 eme- and NO-independent activator of soluble guanylate cyclase [4-([(4-carboxybutyl)[2-(5-fluoro-2-([

43 Ongoing clinical trials have found that guanylate cyclase activating peptides are safe and effec

44 ons were made to rods expressing mutant Y99C guanylate cyclase activating protein (GCAP)-1, to unders

45 to show a direct association between RD3 and guanylate cyclase activating protein 1 (GCAP1).

46 three Ca(2+)-binding proteins, recoverin and guanylate cyclase activating proteins 1 (GCAP1) and GCAP

47 Modulated by Ca(2+) sensors guanylate cyclase activating proteins 1 and 2 (GCAP1 and

48 We studied guanylate cyclase-activating protein 1 (GCAP1) as an exa

49 sites (EF-hands) of the GUCA1A gene encoding guanylate cyclase-activating protein 1 (GCAP1) cause slo

50 o the amino acid substitution p.L176F in the guanylate cyclase-activating protein 1 (GCAP1).

51 We tested direct binding of guanylate cyclase-activating proteins (GCAP1 and GCAP2)

52 Guanylate cyclase-activating proteins (GCAPs) are a fami

53 The guanylate cyclase-activating proteins (GCAPs) are Ca(2+)

54 Guanylate cyclase-activating proteins (GCAPs) link cGMP

55 Mediated by guanylate cyclase-activating proteins (GCAPs), cytoplasm

56 outer segments of GC double knock-out mice, guanylate cyclase-activating proteins 1 and 2, and cycli

57 Treatment with the soluble guanylate cyclase activator BAY41-2272, a vasorelaxing a

58 hodiesterase-5 inhibitors, and now a soluble guanylate cyclase activator have increased therapeutic o

59 Bromo-cGMP, the NO donor SNAP, the guanylate cyclase activator YC-1, and the phosphodiester

60 as phosphodiesterase (PDE)-5 inhibitors and guanylate cyclase activators may represent a promising t

61 l-specific knockout of the ANP receptor with guanylate cyclase activity (betaGC-A-KO).

62 The guanylate cyclase activity and adenylate cyclase activit

63 TNF-alpha also enhanced guanylate cyclase activity and inhibitors of guanylate c

64 guanylate cyclase activity and inhibitors of guanylate cyclase activity blocked the induction of mPGE

65 nding to its extracellular domain stimulates guanylate cyclase activity by an as yet unknown mechanis

66 Blocking soluble guanylate cyclase activity completely suppresses neurite

67 the step is extinguished, and an increase in guanylate cyclase activity during the light step that pe

68 Therefore, the guanylate cyclase activity of BRI1 is modulated by the k

69 sured with suction electrode recordings, and guanylate cyclase activity was measured with the IBMX (3

70 s containing bacterial H-NOX domains exhibit guanylate cyclase activity, but this activity is not inf

71 diazolo[4,3-a]quinoxalin-1-one, a blocker of guanylate cyclase activity.

72 parately, but together the domains exhibited guanylate cyclase activity.

73 an transmembrane receptor carrying intrinsic guanylate cyclase activity.

74 ests additional therapeutic applications for guanylate cyclase agonists.

75 NOS3-/-CSTg), and mice deficient for soluble guanylate cyclase alpha1 (sGCalpha1-/-) were subjected t

76 r inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.

77 sociation of nitric oxide synthase 1/soluble guanylate cyclase and a higher production of cyclic guan

78 ms of CO relied on the activation of soluble guanylate cyclase and calcium-gated potassium channels.

79 inhibition of nitric oxide synthase, soluble guanylate cyclase and cyclo-oxygenase but was blocked by

80 clude binding to the iron centers in soluble guanylate cyclase and cytochrome c oxidase and posttrans

81 lly part of a larger protein such as soluble guanylate cyclase and in prokaryotes where they are ofte

82 Pharmacological inhibition of soluble guanylate cyclase and NOS activity rapidly induces neuri

83 We investigated the role of downstream guanylate cyclase and phosphodiesterase type 5 (PDE5A) e

84 that requires an atypical O2-binding soluble guanylate cyclase and that is sustained until oxygen lev

85 Although expression of guanylate cyclase and/or cGMP-dependent protein kinase (

86 A canonical Galpha-protein, together with guanylate cyclases and cGMP-gated channels, is needed fo

87 l transduction, namely histidine kinases, di-guanylate cyclases and chemotaxis receptors.

88 litating the stability and/or trafficking of guanylate cyclases and maintaining ER and mitochondrial

89 y NO, CO, and O(2), suggesting that atypical guanylate cyclases and NO-sensitive guanylate cyclases h

90 hemical properties of Gyc-88E are unique for guanylate cyclases and suggest a possible function as an

91 of AxCYTcp, the eukaryotic NO sensor soluble guanylate cyclase, and the ferrocytochrome c/cardiolipin

92 1) Both nitric oxide synthase 1 and soluble guanylate cyclase are expressed in higher levels in vasc

93 Transmembrane guanylate cyclases are also important in gastrointestina

94 Soluble guanylate cyclases are nitric oxide-responsive signaling

95 ide/oxygen-binding (H-NOX) domain of soluble guanylate cyclase as a selective NO sensor.

96 tic peptide receptor B (NPR-B [also known as guanylate cyclase B, GC-B, and GUC2B]; gene name NPR2) p

97 ANF-RGC is the prototype membrane guanylate cyclase, both the receptor and the signal tran

98 mechanism that did not require activation of guanylate cyclase but was mimicked by S-nitroso-glutathi

99 ndothelial nitric-oxide synthase and soluble guanylate cyclase, but direct effects on VEGFR2 have not

100 ted process and requires membrane-associated guanylate cyclases, but not typical phosphodiesterases.

101 In contrast, stimulation of soluble guanylate cyclase by NO yields only a weak and transient

102 Guanylate cyclase C (GC-C) is a transmembrane receptor t

103 Guanylate Cyclase C (GC-C) is an apically-oriented trans

104 osome 12 and then sequenced GUCY2C, encoding guanylate cyclase C (GC-C), an intestinal receptor for b

105 activating mutations in intestinal receptor guanylate cyclase C (GC-C), the genetic cause for the ma

106 Guanylate cyclase C (GUCY2C or GC-C) and its ligands, gu

107 Guanylate cyclase C (GUCY2C) and its hormones guanylin a

108 gous to paracrine hormones of the intestinal guanylate cyclase C (GUCY2C) receptor.

109 in-antagonists, chloride channel activators, guanylate cyclase C agonists, atypical benzodiazepines,

110 out cross-reacting with the human endogenous guanylate cyclase C receptor ligands.

111 a minimally absorbed peptide agonist of the guanylate cyclase C receptor.

112 ylin in the brain and activates the receptor guanylate cyclase-C (GC-C) to reduce food intake and pre

113 n these patients presumably by activation of guanylate cyclase-C (GC-C), which stimulates production

114 naclotide is a minimally absorbed agonist of guanylate cyclase-C (GUCY2C or GC-C) that reduces sympto

115 a minimally absorbed peptide agonist of the guanylate cyclase-C receptor that stimulates intestinal

116 y absorbed, 14-amino acid peptide agonist of guanylate cyclase-C, has shown benefit in a proof-of-con

117 is an active kinase and also encapsulates a guanylate cyclase catalytic centre.

118 Mutating the guanylate cyclase center of PSKR1 impairs seedling growt

119 ter 30 min, while cortical release of cyclic guanylate cyclase (cGMP), an index of NOS activity, incr

120 understanding gastrointestinal transmembrane guanylate cyclase/cGMP physiology has recently accelerat

121 l for therapeutic manipulation of intestinal guanylate cyclase/cGMP signaling for the correction of c

122 enated myoglobin activates canonical soluble guanylate cyclase/cGMP signaling pathways.

123 A guanylate cyclase construct containing the juxta-membran

124 affects the efficacy of soluble/particulate guanylate cyclase coupling to cGMP in cardiac dysautonom

125 f olfactory signal transduction, but express guanylate cyclase-D (GC-D).

126 n did wild-type Brucella or the low-c-di-GMP guanylate cyclase DeltacgsB mutant.

127 nase (ERK) phosphorylation was induced via a guanylate cyclase-dependent mechanism.

128 o be observed for any member of the membrane guanylate cyclase family.

129 AQP1 is activated by an endogenous receptor guanylate cyclase for atrial natriuretic peptide (ANP).

130 opportunities aimed at activation of soluble guanylate cyclase for multiple cardiovascular indication

131 e a family of proteins that regulate retinal guanylate cyclase (GC) activity in a Ca2+-dependent mann

132 evels regulate the activity of photoreceptor guanylate cyclase (GC) and the synthesis of cGMP, the in

133 nimals were exquisitely sensitive to NOS and guanylate cyclase (GC) inhibitors (L-NAME, ODQ), which i

134 ein 3 (RD3) is critical in the regulation of guanylate cyclase (GC) signaling and photoreceptor cell

135 studied before and after: (1) inhibition of guanylate cyclase (GC) with and without a NO donor; (2)

136 ls were normal in low-AIPL1 retinas, as were guanylate cyclase (GC), rhodopsin kinase (RK), and norma

137 NO transduces many intracellular signals via guanylate cyclase (GC), we investigated the role of GC,

138 Common downstream effectors of NOS are guanylate cyclase (GC), which synthesizes cyclic GMP, an

139 ny biological effects of NPs are mediated by guanylate cyclase (GC)-coupled NP receptors, NPR-A and N

140 P either by NS-2028 [a specific inhibitor of guanylate cyclase (GC)] or by KT5823 [a specific inhibit

141 Activation of particulate guanylate cyclase (GC-A) by ANP leads to a substantial,

142 Rom1 or peripherin/rds; however, the retinal guanylate cyclases GC1 and GC2 were severely affected in

143 phase of phototransduction by photoreceptor guanylate cyclases (GCs) GC1 (or GC-E) and GC2 (or GC-F)

144 function in the regulation of photoreceptor guanylate cyclases (GCs).

145 l AWC(ON) behavior, requires a receptor-like guanylate cyclase GCY-28 that acts in adults and localiz

146 The soluble guanylate cyclase GCY-35 is required for high oxygen to

147 ed by tax-2 and tax-4 as well as the soluble guanylate cyclase GCY-35.

148 BAG transduction pathway, the receptor-type guanylate cyclase GCY-9, suffices to confer cellular sen

149 ing of a sensory receptor, the receptor-type guanylate cyclase GCY-9, to cilia in chemosensory neuron

150 ide-gated ion channels and the receptor-type guanylate cyclase GCY-9.

151 The soluble guanylate cyclases GCY-35 and GCY-36, which are expresse

152 channel (tax-4 and tax-2) and transmembrane guanylate cyclases (gcy-8, gcy-18 and gcy-23) eliminated

153 rons counterbalance each other via different guanylate cyclases (GCYs) to control lifespan balance.

154 complex regulates the expression of soluble guanylate cyclase genes and other unidentified genes tha

155 ote cell-type-specific expression of soluble guanylate cyclase genes that have key roles in aggregati

156 gene encoding the alpha subunit of a soluble guanylate cyclase (Gucy1A3).

157 These neurons express the soluble guanylate cyclase Gucy1b2 and the cation channel Trpc2.

158 rtension, riociguat, a stimulator of soluble guanylate cyclase, has proven efficacious.

159 atypical guanylate cyclases and NO-sensitive guanylate cyclases have a common molecular mechanism for

160 d channel tax-2/tax-4 and a specific soluble guanylate cyclase homologue, gcy-35.

161 tric oxide initiates LTP(GABA) by activating guanylate cyclase in GABA-releasing nerve terminals.

162 and humans suggests a role for transmembrane guanylate cyclases in intestinal fluid secretion as well

163 ailing the role of a subset of transmembrane guanylate cyclases in the pathophysiology of intestinal

164 by the kinase while cGMP, the product of the guanylate cyclase, in turn inhibits BRI1 kinase activity

165 psis, whereas levels and activity of soluble guanylate cyclase increase.

166 lateral reactions mediated by (*)NO that are guanylate cyclase-independent and rather are dictated by

167 YC-1, an activator of guanylate cyclase, induced mPGES-1.

168 e-treatment of Calu-3 cells with the soluble guanylate cyclase inhibitor 1H-(1,2,4)-oxadiazolo[4,3-a]

169 The guanylate cyclase inhibitor 1H-[1,2,4]oxadiazole[4,3-a]q

170 n of ERK phosphorylation was reversed by the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]q

171 2)O(2)-induced dilation, whereas the soluble guanylate cyclase inhibitor ODQ had no effect.

172 The soluble guanylate cyclase inhibitor oxadiazolo[4,3-alpha]quinoxa

173 mation was completely inhibited by a soluble guanylate cyclase inhibitor, 1H-[1,2,4]oxadiazolo[4,3-a]

174 Similarly, the guanylate cyclase inhibitors 6-anilino-5,8-quinolinedion

175 n and zebrafish (Danio rerio) retinas, and a guanylate cyclase-inhibitory protein (GCIP) has been sho

176 sensory neurons, the odorant receptor ONE-GC guanylate cyclase is a central transduction component of

177 d suggest that activation of a receptor-type guanylate cyclase is an evolutionarily conserved mechani

178 is also unknown how binding of NO to heme in guanylate cyclase is communicated to the catalytic domai

179 e (*)NO ligation of the heme iron of soluble guanylate cyclase is consistent with this perspective, t

180 ced cGMP formation by stimulation of soluble guanylate cyclase is generally accepted as being the mos

181 of cyclic guanosine monophosphate (cGMP) by guanylate cyclase is of critical importance to gastroint

182 The guanylate cyclase is the previously characterized ROS-GC

183 receptor ROS-GC1 (rod outer segment membrane guanylate cyclase) is a vital component of phototransduc

184 of mice lacking one of the two NO-sensitive guanylate cyclase isoforms [NO-GC1 knockout (KO) or NO-G

185 for NO-mediated signaling as occurs through guanylate cyclase, it is not known if this process is tr

186 iac natriuretic peptides ANP and BNP and the guanylate cyclase-linked natriuretic peptide receptors N

187 ration through activation of the particulate guanylate cyclase-linked natriuretic peptide receptors N

188 itric oxide synthase 1 (and possibly soluble guanylate cyclase) may represent a valuable alternative

189 ly to enhance GABA release through a soluble guanylate cyclase-mediated pathway.

190 Atypical soluble guanylate cyclases mediating O(2) responses also contrib

191 xide (NO) activates the NO-sensitive soluble guanylate cyclase (NO-GC, sGC) and triggers intracellula

192 assembled domains of nitric oxide-sensitive guanylate cyclase (NOsGC) remains to be determined.

193 hibited pathological differentiation via the guanylate cyclase NPR2 (natriuretic peptide receptor 2)

194 e current study the conformational change of guanylate cyclase on activation by NO was studied using

195 Our data suggest GLB-5 and the soluble guanylate cyclases operate in close proximity to sculpt

196 , as occurs at the Fe(2+) centres of soluble guanylate cyclase or cytochrome c oxidase.

197 ur through the canonical pathways of soluble guanylate cyclase or protein nitration, but rather throu

198 cological inhibitors of NO synthase, soluble guanylate cyclase, or cGMP-dependent protein kinases (PK

199 n of COX, but was independent of the soluble guanylate cyclase pathway.

200 iomyocyte cGMP synthesis via an eNOS/soluble guanylate cyclase pathway.

201 ansmitter release from photoreceptors by the guanylate cyclase/PDE6 pair in phototransduction.

202 The homeobox gene Emx1 is expressed in three guanylate cyclase(+) populations, two located in the MOE

203 ncentrations of GTN results in activation of guanylate cyclase, production of cGMP, vasodilation in v

204 rived nitric oxide and activation of soluble guanylate cyclase promotes endothelial quiescence and go

205 generate the NO radical, which can activate guanylate cyclase, react with superoxide, or modify prot

206 ide is a novel therapeutic agent, which is a guanylate cyclase receptor agonist that stimulates water

207 evidence indicates that membrane-associated guanylate cyclase receptors regulate intestinal epitheli

208 d as persistent stimulation of photoreceptor guanylate cyclase, representing a gain of function of mu

209 P2Y12 GPVI, PAR1/PAR4, TP, IP receptors, and guanylate cyclase, respectively, in Factor Xa-inhibited

210 nuated by ODQ, a stimulator and inhibitor of guanylate cyclase, respectively.

211 tients, with associated increases in soluble guanylate cyclase responsiveness to NO.

212 ve recently shown that activation of retinal guanylate cyclase (retGC) by GC-activating proteins (GCA

213 Rod outer segment membrane guanylate cyclase (ROS-GC) transduction system is a cent

214 Belonging to the class of so-called soluble guanylate cyclase (sGC) activators, cinaciguat and BAY 6

215 nt of a rapid colorimetric assay for soluble guanylate cyclase (sGC) activity adapted for a 96-well m

216 Modulation of soluble guanylate cyclase (sGC) activity by nitric oxide (NO) in

217 in (GTN), resulting in activation of soluble guanylate cyclase (sGC) and cGMP-mediated vasodilation.

218 lable agent that directly stimulates soluble guanylate cyclase (sGC) and sensitizes it to its physiol

219 Epigenetic regulation of soluble guanylate cyclase (sGC) beta1 in breast cancer cells.

220 insertion into the beta1 subunit of soluble guanylate cyclase (sGC) beta1, which enables it to assoc

221 Activation of soluble guanylate cyclase (sGC) by the signaling molecule nitric

222 ges of heme coordination in purified soluble guanylate cyclase (sGC) by time-resolved spectroscopy in

223 Soluble guanylyl/guanylate cyclase (sGC) converts GTP to cGMP after bindi

224 RATIONALE: Soluble guanylate cyclase (sGC) heme iron, in its oxidized state

225 induces cGMP synthesis by activating soluble guanylate cyclase (sGC) in ventilated lung regions.

226 G)-nitro-L-arginine methyl ester, or soluble guanylate cyclase (sGC) inhibited by 1H-[1,2,4]oxadiazol

227 uanidine; 10 mumol l(-1) , n = 6) or soluble guanylate cyclase (sGC) inhibitor ODQ (1H-[1,2,4]oxadiaz

228 Soluble guanylate cyclase (sGC) is a heme-containing enzyme that

229 Soluble guanylate cyclase (sGC) is a heterodimer composed of alp

230 Soluble guanylate cyclase (sGC) is a heterodimeric, nitric oxide

231 Soluble guanylate cyclase (sGC) is a nitric oxide- (NO-) sensing

232 The heme cofactor in soluble guanylate cyclase (sGC) is a selective receptor for NO,

233 Soluble guanylate cyclase (sGC) is generally regarded as the pri

234 Soluble guanylate cyclase (sGC) is the mammalian endogenous nitr

235 Soluble guanylate cyclase (sGC) is the primary nitric oxide (NO)

236 Soluble guanylate cyclase (sGC) is the primary receptor for the

237 the eye; however, the involvement of soluble guanylate cyclase (sGC) is unknown.

238 Soluble guanylate cyclase (sGC) is weakly activated by carbon mo

239 changes in expression of eNOS, iNOS, soluble guanylate cyclase (sGC) or antioxidant genes.

240 s required for activation of NOS and soluble guanylate cyclase (sGC) serves as a NO receptor.

241 Soluble guanylate cyclase (sGC) serves as a receptor for the sig

242 The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recentl

243 YC-1) is an allosteric stimulator of soluble guanylate cyclase (sGC) that sensitizes the enzyme to th

244 hysiological processes by activating soluble guanylate cyclase (sGC) to produce the second messenger

245 Soluble guanylate cyclase (sGC) uses a ferrous heme cofactor as

246 ery pressure encodes an alpha1-A680T soluble guanylate cyclase (sGC) variant.

247 Soluble guanylate cyclase (sGC) was identified in BMDMOs at a mR

248 a(cat) and beta(cat)) of alpha1beta1 soluble guanylate cyclase (sGC) were expressed in Escherichia co

249 Soluble guanylyl/guanylate cyclase (sGC), a heme-containing heterodimeric

250 Soluble guanylate cyclase (sGC), a hemoprotein, is the primary n

251 Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxid

252 (ODQ) resulted in heme oxidation of soluble guanylate cyclase (sGC), as evident from diminished NO-i

253 ine the role of a downstream signal, soluble guanylate cyclase (sGC), in the regulation of NHGU by NO

254 rties with the eukaryotic NO-sensor, soluble guanylate cyclase (sGC), including 5c-NO formation via t

255 loss of the prosthetic haem group of soluble guanylate cyclase (sGC), preventing its activation by ni

256 or a related species that activates soluble guanylate cyclase (sGC), resulting in cGMP-mediated vaso

257 be eliminated by inhibiting hepatic soluble guanylate cyclase (sGC), suggesting that the sGC pathway

258 Soluble guanylate cyclase (sGC), the mammalian NO sensor, transd

259 Soluble guanylyl/guanylate cyclase (sGC), the primary biological receptor

260 Regulation of soluble guanylate cyclase (sGC), the primary NO receptor, is lin

261 Soluble guanylate cyclase (sGC), the primary NO receptor, trigge

262 The downstream target of NO, soluble guanylate cyclase (sGC), was in somata in the inner and

263 oxide (NO)-independent activators of soluble guanylate cyclase (sGC), YC-1, and BAY-58-2667 on TM cel

264 unctions as the primary activator of soluble guanylate cyclase (sGC).

265 tion of BAY 60-2770, an activator of soluble guanylate cyclase (sGC).

266 ctivity of the downstream NO target, soluble guanylate cyclase (sGC).

267 through activation of the soluble isoform of guanylate cyclase (sGC).

268 tivator of the mammalian hemoprotein soluble guanylate cyclase (sGC).

269 ide capable of activating the enzyme soluble guanylate cyclase (sGC).

270 nding) family of proteins, including soluble guanylate cyclase (sGC).

271 d neurotransmission by activation of soluble guanylate cyclase (sGC).

272 ) produces its effects by activating soluble guanylate cyclase (sGC).

273 elevant activator of the hemoprotein soluble guanylate cyclase (sGC).

274 ting cGMP signaling cascades through soluble guanylate cyclase (sGC).

275 ing the airway smooth muscle enzyme, soluble guanylate cyclase (sGC).

276 ignaling proteins in cells including soluble guanylate cyclase (sGC).

277 tor component, the alpha1 subunit of soluble guanylate cyclase (sGCalpha1), are prone to hypertension

278 Soluble guanylate cyclases (sGCs) are gas-binding proteins that

279 Significance statement: Soluble guanylate cyclases (sGCs) control essential and diverse

280 vels requires cGMP signaling through soluble guanylate cyclases (sGCs), proteins that bind gases thro

281 lagen-1 production did not depend on MAPK or guanylate cyclase signaling pathways but did depend on t

282 target proteins beta-PIX, plakophilin-4, and guanylate cyclase soluble subunit alpha-2 using colocali

283 ervious pulmonary embolism, treatment with a guanylate cyclase stimulator normalized pulmonary hemody

284 rectomy (PEA) who were receiving the soluble guanylate cyclase stimulator riociguat.

285 ulmonary vasodilator reserve using a soluble guanylate cyclase stimulator, BAY 41-8543.

286 Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase

287 hypothesized that riociguat, a novel soluble guanylate cyclase stimulator, would have beneficial hemo

288 member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previo

289 sts, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, a

290 ation of GCY-33 and GCY-35, atypical soluble guanylate cyclases that act as O2 sensors, to the dendri

291 produce NO, leading to production of cGMP by guanylate cyclase, to transduce the extracellular signal

292 dentity of a novel Ca(2+)-modulated membrane guanylate cyclase transduction system in the inner retin

293 The rod outer segment membrane guanylate cyclase type 1 (ROS-GC1), originally identifie

294 and GCAP2 to the full-length membrane-bound guanylate cyclase type 1.

295 GCAP1-L151F stimulation of photoreceptor guanylate cyclase was not completely inhibited at high p

296 between nitric oxide synthase 1 and soluble guanylate cyclase were determined.

297 GLB-5 acts with the atypical soluble guanylate cyclases, which are a different type of oxygen

298 and apoptosis via activation of Akt1/PKB and guanylate cyclase, while HO-1 gene silencing exacerbated

299 ) production with l-NA (100 mum) and soluble guanylate cyclase with 1H-[1,2,4]oxadiazolo[4,3-a]quinox

300 Inhibition of guanylate cyclase with oxadiazoloquinoxalin (ODQ) also i

301 AP2 bound to different regions on the target guanylate cyclase with submicromolar affinity (apparent